Status:
COMPLETED
Progesterone Levels and Clinical Outcomes Using a Single Pessary of 400 mg of Vaginal Progesterone in Substitutive Cycles for Embryo Transfer.
Lead Sponsor:
Instituto Bernabeu
Conditions:
Luteal Phase Defect
Eligibility:
FEMALE
18-50 years
Brief Summary
This study aims to compare the efficacy, in terms of progesterone levels and clinical outcomes, of two different presentations of micronized vaginal progesterone (400 mg vs. 200 mg) used in endometria...
Eligibility Criteria
Inclusion
- Patients with primary or secondary infertility undergoing endometrial preparation for an embryo transfer using standard doses of oral or transdermal estrogens.
- Age between 18 and 50 years.
- Normal uterine cavity verified by imaging techniques.
- Serum progesterone documented on the day of embryo transfer.
Exclusion
- Patients with a history of endometritis.
- Patients diagnosed with Asherman's syndrome.
- Patients with a different supplementation regimen or doses than those of the study groups.
Key Trial Info
Start Date :
March 3 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 17 2021
Estimated Enrollment :
347 Patients enrolled
Trial Details
Trial ID
NCT04722471
Start Date
March 3 2021
End Date
March 17 2021
Last Update
March 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Bernabeu
Alicante, Valencia, Spain, 03016